MGNX Earnings
MacroGenics Inc
$
1.470
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of MacroGenics Inc(MGNX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of MacroGenics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q1 | 2025-05-13 | After Hours | -0.61 | -0.65 | -6.56 | 9.59M | 13.19M | +37.52 | +0.65 | +3.25 |
| FY2024Q4 | 2025-03-20 | After Hours | -0.23 | -0.25 | -8.70 | 34.17M | 19.35M | -43.37 | -5.00 | -29.52 |
| FY2024Q3 | 2024-11-05 | After Hours | 0.08 | 0.90 | +1025.00 | 87.58M | 110.71M | +26.41 | +11.14 | +8.75 |
| FY2024Q2 | 2024-08-06 | - | -0.47 | -0.89 | -89.36 | 20.93M | 10.80M | -48.41 | +1.68 | -6.42 |
| FY2024Q1 | 2024-05-09 | - | -0.67 | -0.84 | -25.37 | 14.86M | 9.10M | -38.73 | +0.07 | -67.87 |
| FY2023Q4 | 2024-03-07 | - | -0.26 | -0.75 | -188.46 | 32.63M | 10.72M | -67.15 | -4.47 | -22.87 |
| FY2023Q3 | 2023-11-06 | - | -0.03 | -0.52 | -1633.33 | 52.12M | 10.40M | -80.05 | +2.45 | +20.53 |
| FY2023Q2 | 2023-08-09 | - | -0.52 | -0.36 | +30.77 | 29.96M | 13.14M | -56.15 | +1.84 | +9.61 |
| - | 2023-05-09 | - | 1.07 | -0.61 | -157.01 | - | - | - | -0.83 | -9.94 |
| - | 2023-03-15 | - | -0.30 | 0.21 | +170.00 | - | - | - | -1.71 | +10.39 |
MGNX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, MacroGenics Inc reported performance for FY2025Q1, announced on 2025-05-13. The company achieved an EPS of -0.65, compared to analyst estimates of -0.61 by -6.56% . Revenue for the quarter reached 13.19M compared to expectations of 9.59M by 37.52% .
The stock price reacted with a 0.65% one-day change and a 3.25% five-day change following the earnings release. These movements reflect market reaction in MacroGenics Inc growth trajectory and strategic initiatives.
MGNX Earnings Forecast
Looking ahead, MacroGenics Inc(MGNX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 28.06M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 46.72%, while EPS estimates have been Revise Upward by 42.27%. For the upcoming , revenue estimates have been adjusted Go Down by -7.55% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in MacroGenics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between MGNX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+46.72%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward
+42.27%
In Past 3 Month
Stock Price
Go Down
-7.55%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:91.68M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price1.47
MGNX Revenue and EPS Performance: A Historical Perspective
MacroGenics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q1 (2025-05-13,After Hours):
EPS: -0.65 (Actual) vs.-0.61 (Estimate) (-6.56%)
Revenue: 13.19M (Actual) vs. 9.59M (Estimate) (37.52%)
Price Reaction: 0.65%(1-Day), 3.25%(5-Day)
FY2024Q4 (2025-03-20,After Hours):
EPS: -0.25 (Actual) vs.-0.23 (Estimate) (-8.70%)
Revenue: 19.35M (Actual) vs. 34.17M (Estimate) (-43.37%)
Price Reaction: -5.00%(1-Day), -29.52%(5-Day)
FY2024Q3 (2024-11-05,After Hours):
EPS: 0.90 (Actual) vs.0.08 (Estimate) (1025.00%)
Revenue: 110.71M (Actual) vs. 87.58M (Estimate) (26.41%)
Price Reaction: 11.14%(1-Day), 8.75%(5-Day)
Earnings Reaction
The chart below shows how MGNX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MGNX sees a +2.63% change in stock price 10 days leading up to the earnings, and a -11.82% change 10 days following the report. On the earnings day itself, the stock moves by -0.59%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed 0.65% on the day following the earnings release and then changed by -9.74% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
MacroGenics Inc (MGNX) Q4 2024 Earnings Call Summary
Neutral
2025-03-20
The earnings call presents mixed signals: strong revenue growth from milestone achievements but significant net losses and increased expenses. The absence of a shareholder return plan and management's unclear responses in the Q&A add uncertainty. However, the optimistic guidance on future clinical trials and potential market expansion balance the negatives. Given these factors, the stock is expected to remain stable in the short term, resulting in a neutral sentiment.
MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Summary
Positive
2024-11-06
The earnings call reflects strong financial performance with a significant increase in revenue and net income, primarily due to milestone payments. The sale of MARGENZA rights and the anticipated upfront payment further strengthen the financial position. Although there are some risks, such as partnership and market risks, the overall sentiment is positive. Additionally, the Q&A session provided insights into ongoing projects and future expectations, with no major negative surprises. Therefore, the stock price is likely to experience a positive movement in the next two weeks.
People Also Watch
EGAN
eGain Corp
5.580
USD
-3.13%
FCCO
First Community Corp (South Carolina)
25.170
USD
+0.88%
ELA
Envela Corp
6.700
USD
+11.85%
EMX
EMX Royalty Corp
3.070
USD
-0.32%
KRMD
KORU Medical Systems Inc
4.040
USD
+2.02%
IVA
Inventiva SA
3.490
USD
-2.51%
DLNG
Dynagas LNG Partners LP
3.615
USD
+0.42%
EPM
Evolution Petroleum Corp
4.930
USD
+2.71%
MOLN
Molecular Partners AG
3.820
USD
+10.72%
NKSH
National Bankshares Inc
29.040
USD
+0.31%
FAQ
What were the key highlights of MGNX’s latest earnings report for FY2025Q1?
MGNX reported its FY2025Q1 earnings on 2025-05-13, showcasing a revenue of 13.19M against an estimate of 9.59M, resulting in a 37.52% surprise. The EPS was -0.65, surpassing the expected -0.61 by -6.56% . The stock experienced a 0.65% price change on the earnings day and a 3.25% change over the next five days, reflecting market reactions to the results.
How did MGNX’s stock price react after the FY2025Q1 earnings release?
What are the revenue and EPS estimates for MGNX for 2025/Q2?
How does MGNX’s stock price correlate with earnings forecast revisions?
What should investors expect from MGNX’s next earnings report?